Triple Combination Metered Dose Inhaler: Tiotropium Bromide + Formoterol + Ciclesonide
In today’s rapidly growing respiratory treatment market, the introduction of a triple combination metered dose inhaler (MDI) is a new innovation. One such innovation is the Tiotropium Bromide + Formoterol Fumarate + Ciclesonide Inhaler as a powerful combination of three important therapeutic agents that provide comprehensive respiratory relief.
At Maya Biotech, a leading third-party pharmaceutical manufacturer, we are proud to offer this latest solution for all pharma brands and franchise partners. The addition of this triple therapy leads to improved patient outcomes, as well as value to both the inhaler franchise and contract manufacturing markets.
The Tiotropium-Formoterol-Ciclesonide inhaler is a fixed-dose combination of three medications:
- Tiotropium Bromide: A LAMA (Long-Acting Muscarinic Antagonist) that helps open the airways.
- Formoterol Fumarate: A LABA (Long-Acting Beta-Agonist) known for its rapid onset of action.
- Ciclesonide: An ICS (Inhaled Corticosteroid) that reduces inflammation in the lungs.
The combination of these drugs provides a targeted, multi-dimensional therapy for asthma and chronic obstructive pulmonary disease (COPD).
Since Sildenafil Oral Spray is absorbed through the oral mucosa, its onset of action is considerably faster than that of traditional Viagra tablets, which take up to 60 minutes to take effect. Sildenafil Oral Spray may begin working in just 15 minutes. For patients looking for a long-lasting alternative to Viagra tablets, Sildenafil Oral Spray is the best option for rapid onset of action.
Advantages of the Tiotropium+ Formoterol+ Ciclesonide Inhaler
- Offers a combination of bronchodilation and anti-inflammatory effects conveniently delivered in a single inhaler.
- Improves lung function and quality of life for patients.
- Reduces asthma and COPD exacerbation frequency.
- Simplifies treatment with the need to use a single device, leading to better compliance.
- More cost-effective than using multiple inhalers
The use of this combination is also beneficial for patients who are not optimally controlled on dual therapy.
Triple Combination MDI for Asthma and COPD
This triple therapy is indicated for patients with moderate or severe asthma or COPD who are persistently symptomatic or have frequent flare-ups despite using dual therapy.
- For Asthma: Provides added anti-inflammatory control in patients where treatment with an ICS and LABA alone is inadequate.
- For COPD: Provides significant efficacy to help reduce exacerbation risk in patients who are at a high risk of exacerbation.
How to Use Tiotropium + Formoterol + Ciclesonide Inhaler:
- Shake the inhaler well before each use.
- Exhale fully and then place the mouthpiece in your mouth.
- Simultaneously push down on the canister and take a deep breath in.
- Hold your breath for 5 to 10 seconds.
- Rinse your mouth after use to reduce the chance of oral thrush.
Tiotropium+ Formoterol + Ciclesonide Inhaler Side Effects:
Common side effects may include:
- Dry mouth
- Headache
- Cough or throat irritation
- Oral thrush (due to the corticosteroid)
- Hoarseness
- Palpitations
Tiotropium + Formoterol + Ciclesonide Inhaler Mechanism of Action:
This inhaler combines three mechanisms of action for synergistic effect:
- Tiotropium blocks M3 receptors in the airways resulting in sustained bronchodilation.
- Formoterol activates β2-adrenergic receptors to relax bronchial muscles quickly and effectively.
- Ciclesonide inhibits inflammatory cell activation and cytokine production, reducing both swelling and mucus.
This mechanism helps to improve disease control and reduce exacerbations.
Third Party Manufacturing and Franchise Opportunities in Inhalers
Maya Biotech is a leading third-party manufacturing provider for inhalers. We offer:
- WHO-GMP compliant manufacturing infrastructure.
- Tailored formulation and branding options.
- Franchise opportunities for metered dose and dry powder inhalers.
- Timely delivery and regulatory support.
- End-to-end solutions from R&D to commercial production.
At Maya Biotech, we offer third-party manufacturing for inhalers, helping our partner pharma brands to introduce this triple combination inhaler under their own brand name. We enable our partners, to provide a cost-effective inhaler without compromising on quality. The Tiotropium Bromide + Formoterol Fumarate + Ciclesonide Inhaler offers a new and exciting opportunity in respiratory care, combining three principal therapies into one ultimate product. Not only will it assist patients, but it represents a strategic product for pharmaceutical brands wishing to enter or expand in the respiratory space.
Interested in inhaler franchise or third-party manufacturing? Consider a partnership with Maya Biotech today to develop and market this advanced therapy under your brand name. Contact us for more details on pricing and minimum order quantities for contract manufacturing or franchise opportunities.
